Wockhardt Ltd., a globally recognized pharmaceutical and biotechnology leader headquartered in Mumbai, India, was established by Dr. Habil Khorakiwala in the 1960s. The company specializes in the development, manufacture, and marketing of formulations, biopharmaceuticals, vaccines, and APIs. With a robust international presence, Wockhardt operates manufacturing facilities across India, the UK, Ireland, France, and the U.S., supported by subsidiaries in these regions. Its diverse product portfolio spans generic and branded medications, OTC products, and innovative biopharmaceutical solutions. A strong focus on R&D drives Wockhardt’s advancements, with state-of-the-art facilities and expert teams dedicated to new therapies and improved healthcare. Committed to societal impact, Wockhardt actively participates in CSR initiatives to enhance healthcare access, education, and welfare for underserved communities.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | |
| Promoters + | 54.93% | 51.60% | 51.99% | 51.99% | 49.09% |
| FIIs + | 4.18% | 5.49% | 5.94% | 6.70% | 6.54% |
| DIIs + | 0.30% | 4.82% | 4.45% | 5.08% | 9.82% |
| Government + | 0.00% | 0.01% | 0.01% | 0.02% | 0.02% |
| Public + | 40.59% | 38.06% | 37.62% | 36.21% | 34.54% |
| No. of Shareholders | 1,61,813 | 1,46,138 | 1,40,391 | 1,38,142 | 1,42,710 |
The shareholding pattern of Wockhardt Ltd. from December 2023 to December 2024 reflects notable shifts. Promoters’ holdings declined from 54.93% in December 2023 to 49.09% by December 2024, indicating reduced ownership. Foreign Institutional Investors (FIIs) increased their stake from 4.18% to 6.54%, peaking at 6.70% in September 2024, showcasing growing confidence. Domestic Institutional Investors (DIIs) exhibited significant growth, rising from 0.30% to 9.82% over the year. Public shareholding steadily decreased from 40.59% to 34.54%, while government ownership remained minimal at around 0.01% to 0.02%. The number of shareholders fluctuated, starting at 1,61,813 in December 2023, dropping to 1,38,142 in September 2024, and slightly recovering to 1,42,710 by December 2024, reflecting dynamic investor interest in Wockhardt during this period.
Latest News on Wockhardt
Wockhardt Hospitals in Mira Road recently achieved a significant milestone by successfully performing their first ABO incompatible swap kidney transplant, a groundbreaking procedure that saved two lives. This complex surgery, which allows kidney transplants between donors and recipients with incompatible blood types, highlights the hospital’s advanced expertise in nephrology and transplantation. This achievement coincides with the hospital reaching another landmark—completing 50 successful kidney transplants—further solidifying its reputation as a leader in kidney care and innovative medical procedures.
Below are the trading platforms that you can use to purchase Wockhardt shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
| When | Maximum Price | Minimum Price |
| April 2025 | 1,451.77 | 1,116.75 |
| May 2025 | 1,409.48 | 1,084.22 |
| June 2025 | 1,472.91 | 1,133.01 |
| July 2025 | 1,444.03 | 1,110.79 |
| August 2025 | 1,488.69 | 1,145.15 |
| September 2025 | 1,506.56 | 1,158.89 |
| October 2025 | 1,545.73 | 1,189.02 |
| November 2025 | 1,584.37 | 1,218.75 |
| December 2025 | 1,655.67 | 1,273.59 |
As we step into 2025, Wockhardt’s share price is expected to showcase a steady upward momentum. By April 2025, the maximum share price is anticipated to reach ₹1,451.77, while the minimum share price may be around ₹1,116.75. Moving forward, by December 2025, the maximum share price is projected to rise significantly to ₹1,655.67, with the minimum share price estimated at ₹1,273.59.
| When | Maximum Price | Minimum Price |
| January 2026 | 1,705.34 | 1,311.80 |
| February 2026 | 1,662.70 | 1,279.00 |
| March 2026 | 1,695.96 | 1,304.58 |
| April 2026 | 1,730.57 | 1,331.21 |
| May 2026 | 1,713.43 | 1,318.03 |
| June 2026 | 1,756.27 | 1,350.98 |
| July 2026 | 1,721.83 | 1,324.49 |
| August 2026 | 1,775.09 | 1,365.45 |
| September 2026 | 1,810.59 | 1,392.76 |
| October 2026 | 1,857.66 | 1,428.97 |
| November 2026 | 1,904.10 | 1,464.70 |
| December 2026 | 1,951.71 | 1,501.31 |
As we move into 2026, Wockhardt’s share price is anticipated to experience a consistent upward trend. By January 2026, the maximum share price is expected to reach ₹1,705.34, while the minimum share price may be around ₹1,311.80. Progressing through the year, by December 2026, the maximum share price is projected to rise substantially to ₹1,951.71, with the minimum share price estimated at ₹1,501.31.
| When | Maximum Price | Minimum Price |
| January 2027 | 1,971.22 | 1,516.33 |
| February 2027 | 2,021.77 | 1,555.21 |
| March 2027 | 2,100.62 | 1,615.86 |
| April 2027 | 2,059.43 | 1,584.18 |
| May 2027 | 1,999.44 | 1,538.03 |
| June 2027 | 2,089.42 | 1,607.25 |
| July 2027 | 2,048.45 | 1,575.73 |
| August 2027 | 2,111.80 | 1,624.47 |
| September 2027 | 2,185.72 | 1,681.32 |
| October 2027 | 2,242.55 | 1,725.04 |
| November 2027 | 2,298.61 | 1,768.16 |
| December 2027 | 2,356.08 | 1,812.37 |
| When | Maximum Price | Minimum Price |
| January 2028 | 2,403.20 | 1,848.61 |
| February 2028 | 2,464.82 | 1,896.01 |
| March 2028 | 2,560.95 | 1,969.96 |
| April 2028 | 2,510.73 | 1,931.33 |
| May 2028 | 2,437.60 | 1,875.08 |
| June 2028 | 2,547.29 | 1,959.46 |
| July 2028 | 2,497.35 | 1,921.04 |
| August 2028 | 2,574.59 | 1,980.45 |
| September 2028 | 2,664.70 | 2,049.77 |
| October 2028 | 2,733.98 | 2,103.06 |
| November 2028 | 2,802.33 | 2,155.64 |
| December 2028 | 2,872.39 | 2,209.53 |
| When | Maximum Price | Minimum Price |
| January 2029 | 2,929.83 | 2,253.72 |
| February 2029 | 3,004.96 | 2,311.51 |
| March 2029 | 3,122.15 | 2,401.65 |
| April 2029 | 3,060.93 | 2,354.56 |
| May 2029 | 2,971.78 | 2,285.98 |
| June 2029 | 3,105.51 | 2,388.85 |
| July 2029 | 3,044.62 | 2,342.01 |
| August 2029 | 3,138.78 | 2,414.45 |
| September 2029 | 3,248.64 | 2,498.95 |
| October 2029 | 3,333.10 | 2,563.92 |
| November 2029 | 3,416.43 | 2,628.02 |
| December 2029 | 3,501.84 | 2,693.72 |
| When | Maximum Price | Minimum Price |
| January 2030 | 3,571.88 | 2,747.60 |
| February 2030 | 3,663.46 | 2,818.05 |
| March 2030 | 3,806.34 | 2,927.95 |
| April 2030 | 3,731.70 | 2,870.54 |
| May 2030 | 3,623.01 | 2,786.93 |
| June 2030 | 3,786.05 | 2,912.35 |
| July 2030 | 3,711.81 | 2,855.24 |
| August 2030 | 3,826.61 | 2,943.55 |
| September 2030 | 3,960.54 | 3,046.57 |
| October 2030 | 4,063.52 | 3,125.78 |
| November 2030 | 4,165.11 | 3,203.93 |
| December 2030 | 4,269.23 | 3,284.03 |
As we progress into 2030, Wockhardt’s share price is expected to display significant growth throughout the year. By January 2030, the maximum share price is anticipated to reach ₹3,571.88, while the minimum share price may hover around ₹2,747.60. Advancing further, by December 2030, the maximum share price is projected to climb to an impressive ₹4,269.23, with the minimum share price estimated at ₹3,284.03.
Financial Condition of Wockhardt
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
| Sales + | 2,844 | 2,708 | 3,230 | 2,651 | 2,798 | 2,969 |
| Expenses + | 2,725 | 2,771 | 2,932 | 2,549 | 2,707 | 2,699 |
| Operating Profit | 119 | -63 | 298 | 102 | 91 | 270 |
| OPM % | 4% | -2% | 9% | 4% | 3% | 9% |
| Other Income + | 133 | 975 | -163 | -173 | 17 | 57 |
| Interest | 276 | 249 | 299 | 302 | 305 | 279 |
| Depreciation | 224 | 246 | 247 | 251 | 223 | 222 |
| Profit before tax | -247 | 417 | -411 | -624 | -420 | -174 |
| Tax % | -82% | -65% | -32% | 0% | 12% | |
| Net Profit + | -43 | 688 | -279 | -621 | -472 | -189 |
| EPS in Rs | -4.81 | 47.64 | -16.94 | -38.8 | -30.18 | -12.5 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Wockhardt’s financial performance over the years reflects a journey marked by both challenges and progress. Sales for Wockhardt fluctuated, starting at ₹2,844 crore in March 2020, declining to ₹2,651 crore in March 2023, but recovering to ₹2,798 crore in March 2024, with a TTM (Trailing Twelve Months) value of ₹2,969 crore. Despite these fluctuations, expenses remained relatively consistent, reaching ₹2,699 crore in the TTM period, showcasing efficient cost management.
Operating profit exhibited a mixed trend, starting at ₹119 crore in March 2020 and improving to ₹270 crore in the TTM period, with the OPM% (Operating Profit Margin) rising from 4% to 9%. However, other income displayed volatility, peaking at ₹975 crore in March 2021 but turning negative in subsequent years before recovering slightly to ₹57 crore in the TTM period. Interest and depreciation remained steady, with TTM values at ₹279 crore and ₹222 crore, respectively.
Wockhardt’s profitability faced challenges, with net profit turning negative after March 2021, reflecting losses of ₹621 crore in March 2023 and ₹472 crore in March 2024. The EPS (Earnings Per Share) followed a similar trajectory, declining to ₹-38.80 in March 2023 and further to ₹-30.18 in March 2024, with a TTM figure of ₹-12.50. Dividend payout remained at 0% across all years, indicating a reinvestment-focused approach.
FAQs
What is Wockhardt current market capitalization?
Wockhardt current market capitalization is ₹20,918 crore.
The projected share price target for Wockhardt in 2025 ranges from ₹1,084.22 to ₹1,655.67.
The projected share price target for Wockhardt in 2030 ranges from ₹2,747.60 to ₹4,269.23.
What is the dividend payout percentage for Wockhardt?
Wockhardt dividend payout percentage is 0%.
Also Read
- IFB Industries Share Price Target 2025, 2026, 2027 to 2030
- Healthcare Global Enterprises Share Price Target 2025, 2026, 2027 to 2030
- Amber Enterprises India Share Price Target 2025, 2026 to 2030
Conclusion
Wockhardt Ltd., a global pharmaceutical and biotech leader, focuses on innovative therapies, biosimilars, and improving healthcare access. Despite financial challenges, it has strengthened its pipeline through global collaborations and strategic initiatives. Recent news highlights operational optimizations and investor interest, with institutional holdings rising and promoter stakes declining. Future projections suggest steady growth, with prices potentially reaching ₹4,269.23 by December 2030. With its focus on innovation and partnerships, Wockhardt is poised for long-term success.
Having said that, we are not a financial advisor. Please consult a SEBI-registered financial advisor before trading Wockhardt. This post on Wockhardt share price target from 2025 to 2030 is for educational purposes only.
What did we learn?
